[1] Liu YR, Zhan SY, Zheng BH, et al.Advancement on pharma-cokinetics study of traditional Chinese medicine injection in recent ten years[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2021,46(7): 1752-1762. [2] Atkinson AJ, Jr., Abernethy DR, Daniels CE, et al. Principle of clinical pharmacology (second edition)[M]. Elsevier Inc, 2007. [3] Yuan SJ.Mathematical flaws of commonly used calculating methods of multi-drug combination and solution based on one belt and one line model method[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(1): 11-17, 29. [4] Li J. Clinical Pharmacology(临床药理学)[M]. Beijing: People's Medical Publishing House, 2013. [5] National Medical Products Administration. Guidelines for drug interaction research[EB/OL].(2012-05-15)[2021-03-16]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20120515120001975.html. [6] Center for drug evaluation, NMPA. Announcement of the Center for Drug Evaluation of the National Medical Products Administration on the Issuance of“Technical Guidelines for Drug Interaction Research (Trial)”(No. 4 of 2021) [EB/OL]. (2021-01-25)[2021-03-16]. http://www.cde.org.cn/news.do?method=largeInfo&id=cc85bdbe69af7f7a. [7] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, clinical drug interaction studies-cytochrome P450 enzyme and transporter-mediated drug interactions[EB/OL]. (2020-01) [2021-03-16]. https://www.fda.gov/media/134581/download. [8] Committee for Human Medicinal Products (CHMP), European Medicines Agency. Guideline on the investigation of drug interactions[EB/OL]. (2012-06-21) [2021-03-16]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions_en.pdf. [9] Ministry of Labor and Welfare. Guideline on drug interaction for drug development and appropriate provision of information, notification No.0723-4, pharmaceutical evaluation division pharmaceuticals safety and environmental Health bureau, Japan[EB/OL]. (2019-02-08) [2021-03-16]. https://www.pmda.go.jp/files/000228122.pdf. [10] Ishiguro A, Sato R, Nagai N.Development of a new Japanese guideline on drug interaction for drug development and appropriate provision of information[J]. Drug Metabolism and Pharmacokinetics, 2020, 35(1): 12-17. [11] Venkatakrishnan K, Rostami-Hodjegan A.Come dance with me: transformative changes in the science and practice of drug-drug interactions[J]. Clinical Pharmacology and Therapeutics, 2019, 105(6): 1272-1278. [12] Hennessy S, Leonard CE, Gagne JJ, et al.Pharmacoepidemiologic methods for studying the health effects of drug-drug interactions[J]. Clinical Pharmacology and Therapeutics, 2016, 99(1): 92-100. [13] Juurlink DN, Mamdani M, Kopp A, et al.Drug-drug interactions among elderly patients hospitalized for drug toxicity[J]. JAMA, 2003, 289(13): 1652-1658. [14] Li H, Deng J, Yue Z, et al.Detecting drug-herbal interaction using a spontaneous reporting system database: an example with benzylpenicillin and qingkailing injection[J]. European Journal of Clinical Pharmacology, 2015, 71(9): 1139-1145. [15] Rekić D, Reynolds KS, Zhao P, et al.Clinical drug-drug interaction evaluations to inform drug use and enable drug access[J]. Journal of Pharmaceutical Sciences, 2017, 106(9): 2214-2218. [16] Li X, Liu RN, Liu ZJ.Interpretation of clinical drug interaction studies—study design, data analysis, and clinical implications guidance for industry (draft guidance)[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2019, 21(1): 43-49. [17] Tornio A, Filppula AM, Niemi M, et al.Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation[J]. Clinical Pharmacology and Therapeutics, 2019, 105(6): 1345-1361. [18] Yeung KS, Gubili J, Mao JJ.Herb-drug interactions in cancer care[J]. Oncology (Williston Park, NY), 2018, 32(10): 516-520. [19] Gurley BJ, Yates CR, Markowitz JS.“…Not Intended to Diagnose, Treat, Cure or Prevent Any Disease.”25 Years of botanical dietary supplement research and the lessons learned[J]. Clinical Pharmacology and Therapeutics, 2018, 104(3): 470-483. [20] Tian SD, Chen XY.Characteristics and advantages of Chinese medicine in the treatment of malignant tumors[J]. Modern Chinese Clinical Medicine(现代中医临床), 2019, 26(2): 8-17. [21] Liu K, Luo H, Liu JP.Exploration on methodology of clinical evaluation about advers drug reaction of interaction between Chinese herbs and western drug[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2010, 7(12): 719-721. [22] Xie YM, Wang LX, Wang YY.Exploration and demonstration study on drug combination from clinical real world[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2014, 39(18): 3424-3426. [23] Zheng R, Chen SQ, Shang HC.The safety evaluation method of herb-drug combination: manifestation-target alliance[J]. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica(世界科学技术-中医药现代化), 2018, 20(10): 1734-1738. [24] Li J, E.Olaleye O, Yu X, et al. High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis care[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2020, 25(4): 361-363. [25] Li J, Olaleye OE, Yu X, et al.High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis care[J]. Acta Pharmaceutica Sinica B, 2019, 9(5): 1035-1049. [26] Cheng JL, Ouyang HT, Jin HT, et al.Thoughts and suggestions on safety evaluation of combined use of traditional Chinese medicine in clinical research[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(1): 4-10. [27] Mills E, Wu P, Johnston BC, et al.Natural health product-drug interactions: a systematic review of clinical trials[J]. Therapeutic Drug Monitoring, 2005, 27(5): 549-557. [28] Kennedy DA, Seely D.Clinically based evidence of drug-herb interactions: a systematic review[J]. Expert Opinion On Drug Safety, 2010, 9(1): 79-124. [29] Gurley BJ, Markowitz JS, Williams DK.Practical considerations when designing and conducting clinical pharmacokinetic herb-drug interaction studies[J]. International Journal of Pharmacokinetics, 2017, 2(1): 57-69. [30] Center of Excellence for Natural Product-Drug Interaction Research. About NaPDI[EB/OL].[2021-03-16]. https://napdicenter.org/about. [31] Johnson EJ, González-Peréz V, Tian DD, et al.Selection of priority natural products for evaluation as potential precipitants of natural product-drug interactions: a NaPDI center recommended approach[J]. Drug metabolism and disposition: the biological fate of chemicals, 2018, 46(7): 1046-1052. [32] Kellogg JJ, Paine MF, Mccune JS, et al.Selection and characte-rization of botanical natural products for research studies: a NaPDI center recommended approach[J]. Natural Product Reports, 2019, 36(8): 1196-1221. [33] Paine MF, Shen DD, Mccune JS.Recommended approaches for pharmacokinetic natural product-drug interaction research: a NaPDI center commentary[J]. Drug Metabolism And Disposition: The Biological Fate Of Chemicals, 2018, 46(7): 1041-1045. [34] Weber WJ, Hopp DC.National center for complementary and integrative health perspectives on clinical research involving natural products[J]. Drug Etabolism and Disposition: The Biological Fate Of Chemicals, 2020, 48(10): 963-965. [35] De Kesel PM, Lambert WE, Stove CP.Alternative sampling strategies for cytochrome P450 phenotyping[J]. Clinical Pharma-cokinetics, 2016, 55(2): 169-184. [36] Nicholson JK, Lindon JC, Holmes E.‘Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica; the Fate of Foreign Compounds In Biological Systems, 1999, 29(11): 1181-1189. [37] Magliocco G, Thomas A, Desmeules J, et al.Phenotyping of human CYP450 enzymes by endobiotics: current knowledge and methodological approaches[J]. Clinical Pharmacokinetics, 2019, 58(11): 1373-1391. [38] Wang XM.Application of metabolomics in the research of chinese herbal medicine[J]. Gansu Science and Technology(甘肃科技), 2019, 35(18): 64-68. [39] Huang WY, Zhang YM, Hao JJ, et al.A rational usage of combined using of herbal medicines and synthetic medicines: a time interval window research[J]. Chinese Science Bulletin(科学通报), 2019, 64(Z2): 3020-3029. [40] Li XP, Wang Y, Lu G, et al.Application of PET molecular imaging technology to pharmacokinetics[J]. Int J Radiat Med Nucl Med(国际放射医学核医学杂志), 2019, 43(4): 349-355. |